Indian pharmaceutical company Lupin's shares gained nearly 2% and hit a 52-week high of ₹830.30 in early trade on Monday. This comes after the Mumbai-headquartered company announced the launch of Darunavir tablets, which are used to treat and prevent HIV/AIDS, in USA. Notably, Lupin posted a consolidated net profit of ₹236 crore for the January-March quarter.